Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the eleven research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and ten have issued a buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $134.30.
Several equities analysts recently commented on the stock. Barclays boosted their price objective on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research note on Monday, April 27th. BTIG Research reiterated a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research note on Monday, July 13th. Piper Sandler reissued an “overweight” rating and issued a $180.00 price target on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. UBS Group boosted their price target on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Finally, Wedbush set a $165.00 price target on shares of Oruka Therapeutics in a report on Monday, April 27th.
View Our Latest Report on ORKA
Oruka Therapeutics Price Performance
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.04. Sell-side analysts expect that Oruka Therapeutics will post -2.06 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, Director Carl Dambkowski sold 12,583 shares of the business’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $70.11, for a total transaction of $882,194.13. Following the completion of the transaction, the director directly owned 38,743 shares in the company, valued at $2,716,271.73. The trade was a 24.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 9,999 shares of the company’s stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $84.63, for a total value of $846,215.37. Following the completion of the transaction, the senior vice president owned 15,312 shares in the company, valued at $1,295,854.56. This represents a 39.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 188,406 shares of company stock worth $12,019,683 over the last three months. Corporate insiders own 23.49% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of ORKA. Royal Bank of Canada increased its position in shares of Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares during the last quarter. Kennedy Capital Management LLC lifted its position in Oruka Therapeutics by 0.9% during the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock valued at $1,476,000 after purchasing an additional 420 shares during the last quarter. AlphaCentric Advisors LLC grew its stake in Oruka Therapeutics by 5.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock worth $564,000 after buying an additional 626 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Oruka Therapeutics by 35.0% in the 4th quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock worth $92,000 after buying an additional 788 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Oruka Therapeutics by 62.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock worth $71,000 after buying an additional 904 shares in the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.
About Oruka Therapeutics
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Featured Stories
- Five stocks we like better than Oruka Therapeutics
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
